Description

SLU-PP-332 is an experimental compound designed to mimic the metabolic effects of exercise
by activating estrogen-related receptors (ERRs), particularly ERRα, ERRβ, and ERRγ. This
activation leads to increased energy expenditure, enhanced fatty acid oxidation, and improved
mitochondrial function.
Metabolic Benefits in Obese Mice: SLU-PP-332 administration in diet-induced obese or
genetically obese (ob/ob) mice resulted in increased energy expenditure and fatty acid oxidation.
These metabolic changes were accompanied by decreased fat mass accumulation, suggesting
potential therapeutic applications for metabolic disorders. SLU-PP-332 has been shown to
promote weight loss and reduce fat accumulation in obese mice without affecting food intake or
requiring increased physical activity. (A study published in the Journal of Pharmacology and
Experimental Therapeutics)
Enhanced Exercise Endurance: SLU-PP-332 increased the proportion of oxidative muscle
fibers in mice, leading to enhanced exercise endurance. This effect was attributed to improved
mitochondrial function and cellular respiration in skeletal muscle cells. (A Research reported
in ACS Chemical Biology)
Potential Treatment for Heart Failure: SLU-PP-332 improved cardiac function in mouse
models of heart failure. The compound enhanced mitochondrial ultrastructure and upregulated
pathways associated with oxidative phosphorylation and fatty acid metabolism, suggesting its
potential as a therapeutic agent for heart failure. (The Studies presented by the American
Chemical Society)
Everyone knows that repetitive physical exercise leads to improved health and wellness.
Research has repeatedly revealed that exercise can thwart heart disease, fight obesity,
improve mood, boost cognitive function, and even help to prevent/treat a number of diseases.
For the most part, attempts to replicate the benefits of exercise using pharmaceuticals has
fallen short. Even weight loss drugs were a bust until the recent advent of peptides like
semaglutide and liraglutide a new breakthrough is underway, however, and researchers have
developed a compound that can replicate some of the benefits of exercise. SLU-PP-332 is an
estrogen-related receptor (ERR) agonist that binds primarily to ERR subclasses alpha and
gamma. It has been shown to improve skeletal muscle endurance, boost weight loss, improve
cardiovascular health, and protect the central nervous system against the ravages of aging and
disease. SLU-PP-332 is the closest science has yet come to replicating the effects of exercise
and has, predictably, generated a great deal of interest in research circles.
Metabolic Benefits in Obese Mice: SLU-PP-332 administration in diet-induced obese or
genetically obese (ob/ob) mice resulted in increased energy expenditure and fatty acid oxidation.
These metabolic changes were accompanied by decreased fat mass accumulation, suggesting
potential therapeutic applications for metabolic disorders. SLU-PP-332 has been shown to
promote weight loss and reduce fat accumulation in obese mice without affecting food intake or
requiring increased physical activity. (A study published in the Journal of Pharmacology and
Experimental Therapeutics)
Enhanced Exercise Endurance: SLU-PP-332 increased the proportion of oxidative muscle
fibers in mice, leading to enhanced exercise endurance. This effect was attributed to improved
mitochondrial function and cellular respiration in skeletal muscle cells. (A Research reported
in ACS Chemical Biology)
Potential Treatment for Heart Failure: SLU-PP-332 improved cardiac function in mouse
models of heart failure. The compound enhanced mitochondrial ultrastructure and upregulated
pathways associated with oxidative phosphorylation and fatty acid metabolism, suggesting its
potential as a therapeutic agent for heart failure. (The Studies presented by the American
Chemical Society)
Everyone knows that repetitive physical exercise leads to improved health and wellness.
Research has repeatedly revealed that exercise can thwart heart disease, fight obesity,
improve mood, boost cognitive function, and even help to prevent/treat a number of diseases.
For the most part, attempts to replicate the benefits of exercise using pharmaceuticals has
fallen short. Even weight loss drugs were a bust until the recent advent of peptides like
semaglutide and liraglutide a new breakthrough is underway, however, and researchers have
developed a compound that can replicate some of the benefits of exercise. SLU-PP-332 is an
estrogen-related receptor (ERR) agonist that binds primarily to ERR subclasses alpha and
gamma. It has been shown to improve skeletal muscle endurance, boost weight loss, improve
cardiovascular health, and protect the central nervous system against the ravages of aging and
disease. SLU-PP-332 is the closest science has yet come to replicating the effects of exercise
and has, predictably, generated a great deal of interest in research circles.